Bharat Biotech’s Covaxin has emerged as the first COVID-19 vaccine worldwide to be used for inoculating children as young as 2 years old with the subject expert committee (SEC) that counsels the Drugs Controller General of India (DCGI) endorsing emergency use authorisation (EUA) for the vaccine for kids in the 2-18 years age group.
Bharat Biotech stated that it had submitted data from clinical trials in the 2-18 years age group for Covaxin (BBV152) to CDSCO.
“The data has been comprehensively evaluated by the CDSCO and SEC have provided their positive approvals,” the company stated.
“This signifies one of the first approvals globally for COVID-19 vaccines for the 2-18 age group. Bharat Biotech genuinely express thanks to the DCGI, SEC and CDSCO for their expedited review process. We now expect further regulatory approvals from the CDSCO prior to vaccine launch and market availability of Covaxin for children,” Bharat Biotech statement added.
Source: IBEF
You may also like
-
Ayurveda and Diabetes Prevention: Lifestyle Lessons from Classical Principles
-
India Examines Regulatory Reforms to Allow Global Pharmaceutical Companies to Conduct First-in-Human Clinical Trials
-
CSIR-CCMB Scientists Identify New Potential Drug Targets Against Tuberculosis Bacterium
-
Ayurveda for Healthy Metabolism: Balancing Agni, Nutrition and Daily Living
-
India Records 38% Decline in TB Mortality, Achieves 94% Treatment Success Rate
